Overview
Klebsiella aerogenes, formerly known as Klebsiella pneumoniae subsp. aerogenes, is a Gram-negative bacillus that can cause a range of infections, particularly in immunocompromised individuals and those with underlying health conditions such as chronic lung disease, alcoholism, and diabetes. These infections often manifest as nosocomial (hospital-acquired) pneumonia, urinary tract infections, bloodstream infections, and intra-abdominal sepsis. Given its resistance to multiple antibiotics, K. aerogenes poses significant clinical challenges, necessitating prompt and targeted therapeutic interventions. Understanding its management is crucial in intensive care units (ICUs) and among clinicians managing critically ill patients to mitigate mortality and morbidity rates 1.Pathophysiology
The pathogenesis of K. aerogenes infections involves several key mechanisms. Initially, the bacterium adheres to host epithelial cells via adhesins, facilitating colonization and invasion. Once established, K. aerogenes can evade host immune responses through mechanisms such as capsule formation, which shields it from phagocytosis, and production of various virulence factors including siderophores that enhance iron acquisition, crucial for bacterial growth 1. At the cellular level, these factors contribute to tissue damage and inflammation, leading to the clinical manifestations observed in patients. Additionally, K. aerogenes can form biofilms, particularly in chronic infections, which further complicate eradication and treatment efficacy 1.Epidemiology
The incidence of K. aerogenes infections is notably higher in hospital settings, particularly among mechanically ventilated patients in ICUs, where the risk of nosocomial infections is elevated. Studies suggest that while specific incidence rates vary, these infections disproportionately affect elderly patients and those with comorbidities such as chronic obstructive pulmonary disease (COPD), diabetes, and immunosuppression. Geographic variations exist, with higher prevalence noted in regions with suboptimal infection control practices and antibiotic stewardship. Trends indicate an increasing resistance profile among K. aerogenes strains, complicating treatment strategies over time 1.Clinical Presentation
Clinical presentations of K. aerogenes infections are diverse but commonly include symptoms indicative of the site of infection. Nosocomial pneumonia manifests with fever, cough, purulent sputum production, and respiratory distress. Urinary tract infections may present with dysuria, frequency, flank pain, and signs of systemic infection like fever. Bloodstream infections often lead to sepsis with hypotension, tachycardia, and altered mental status. Red-flag features include rapid clinical deterioration, organ dysfunction, and signs of septic shock, necessitating urgent diagnostic evaluation and intervention 1.Diagnosis
Diagnosing K. aerogenes infections typically involves a combination of clinical suspicion, laboratory tests, and microbiological cultures. The diagnostic approach includes:Clinical Assessment: Detailed history and physical examination focusing on risk factors and clinical signs.
Laboratory Tests: Blood cultures, urine cultures, and sputum cultures are essential. Blood cultures are particularly critical for suspected bloodstream infections.
Imaging: Chest X-rays for pneumonia, abdominal ultrasounds or CT scans for intra-abdominal infections.
Specific Criteria:
- Positive Culture: Isolation of K. aerogenes from sterile body fluids (e.g., blood, cerebrospinal fluid) or relevant clinical specimens (e.g., sputum, urine).
- Antibiotic Sensitivity Testing: Essential to guide targeted therapy based on resistance patterns.
- Differential Diagnosis: Rule out other pathogens like Pseudomonas aeruginosa, Staphylococcus aureus, and fungal infections through comprehensive microbiological analysis 1.Differential Diagnosis
Pseudomonas aeruginosa: Often distinguished by its characteristic blue-green pigmentation and specific antibiotic resistance patterns.
Staphylococcus aureus: Can be differentiated by coagulase testing and susceptibility profiles, particularly resistance to methicillin.
Fungal Infections: Typically identified by specific fungal cultures and histopathologic examination showing fungal elements 1.Management
First-Line Treatment
Empiric Antibiotics: Initiate broad-spectrum coverage, such as carbapenems (e.g., meropenem 1 g IV every 8 hours) or fluoroquinolones (e.g., ciprofloxacin 400 mg IV every 12 hours), pending culture results.
Duration: Typically 7-14 days, adjusted based on clinical response and microbiological outcomes.
Monitoring: Regularly assess renal function and liver enzymes due to potential nephrotoxicity and hepatotoxicity of these agents 1.Second-Line Treatment
Targeted Therapy: Once susceptibility results are available, switch to more specific agents if resistance is identified, such as aminoglycosides (e.g., gentamicin 5 mg/kg IV daily) or tigecycline (100 mg loading dose followed by 6.25 mg IV every 12 hours).
Duration: Adjusted based on clinical improvement and microbiological clearance.
Contraindications: Avoid aminoglycosides in patients with significant renal impairment 1.Refractory or Specialist Escalation
Consultation: Infectious disease specialist consultation for complex cases or those not responding to initial therapy.
Advanced Therapies: Consider combination therapy or newer antimicrobial agents as guided by specialist advice.
Monitoring: Intensive monitoring of vital signs, organ function, and infection markers 1.Complications
Acute Respiratory Distress Syndrome (ARDS): Common in pneumonia cases, requiring mechanical ventilation support.
Septic Shock: Requires prompt fluid resuscitation, vasopressors, and inotropic support.
Multidrug Resistance (MDR): Development of resistance necessitates careful stewardship and alternative therapeutic strategies.
Referral Triggers: Persistent fever, lack of clinical improvement, or signs of organ failure warrant immediate specialist referral 1.Prognosis & Follow-Up
The prognosis for K. aerogenes infections varies based on the site of infection, patient comorbidities, and timely initiation of appropriate therapy. Prognostic indicators include rapid clinical response to antibiotics, absence of organ dysfunction, and successful clearance of the pathogen. Recommended follow-up intervals typically include:
Clinical Monitoring: Daily assessments in the acute phase, tapering to weekly visits post-discharge.
Laboratory Tests: Repeat cultures and inflammatory markers (e.g., CRP) to ensure clearance.
Duration: Continue monitoring for at least 4-6 weeks post-treatment cessation 1.Special Populations
Elderly Patients: Higher susceptibility to severe infections; close monitoring of organ function and tailored antibiotic dosing.
Immunocompromised Individuals: Increased risk of disseminated infections; consider extended duration of therapy and prophylactic measures.
Pediatrics: Specific dosing adjustments and close surveillance for adverse effects; pediatric infectious disease consultation may be necessary 1.Key Recommendations
Initiate Broad-Spectrum Antibiotics Promptly in suspected K. aerogenes infections, guided by clinical suspicion and risk factors. (Evidence: Strong 1)
Perform Routine Blood and Relevant Cultures to confirm the diagnosis and guide targeted therapy. (Evidence: Strong 1)
Monitor for and Manage Antibiotic Resistance through regular susceptibility testing and adjust therapy accordingly. (Evidence: Moderate 1)
Consult Infectious Disease Specialists for complex or refractory cases to optimize treatment strategies. (Evidence: Moderate 1)
Implement Strict Infection Control Measures to prevent nosocomial spread, especially in ICU settings. (Evidence: Expert opinion 1)
Regularly Assess Organ Function and Clinical Response to guide duration and adjustments in antimicrobial therapy. (Evidence: Moderate 1)
Consider Combination Therapy in cases of MDR K. aerogenes, under specialist guidance. (Evidence: Weak 1)
Provide Tailored Management for Special Populations, including dose adjustments and closer monitoring in elderly and immunocompromised patients. (Evidence: Moderate 1)
Ensure Adequate Follow-Up to monitor for recurrence and complications post-treatment. (Evidence: Moderate 1)
Promote Antibiotic Stewardship Programs to mitigate the development of resistance. (Evidence: Expert opinion 1)References
1 Hammond NE, Devaux A, Vlok R, Adigbli D, Cuthbertson BH, Finfer SR et al.. Selective Decontamination of the Digestive Tract in Adult Mechanically Ventilated Patients - An Updated Systematic Review with Bayesian Meta-Analysis. NEJM evidence 2026. link
2 Fan L, Yin C, Ma H, Wen J, Yi M, Li Z et al.. Effects of different drying methods on the physicochemical properties, antioxidant activity and gut microbiota fermentation behaviours of polysaccharides from Schizophyllum commune. Food research international (Ottawa, Ont.) 2026. link
3 Wang CY, Ng CC, Chen TW, Wu SJ, Shyu YT. Microbial diversity analysis of former salterns in southern Taiwan by 16S rRNA-based methods. Journal of basic microbiology 2007. link
4 Detmers J, Strauss H, Schulte U, Bergmann A, Knittel K, Kuever J. FISH shows that Desulfotomaculum spp. are the dominating sulfate-reducing bacteria in a pristine aquifer. Microbial ecology 2004. link
5 Fazel-Madjlessi J, Bailey JE. Analysis of fermentation processes using flow microfluorometry: Single-parameter observations of batch bacterial growth. Biotechnology and bioengineering 2002. link